// App-Quantinova.ai

: Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214.

Researchers

Presenter

  • David F. McDermott

Principal Investigators

  • Robert J. Motzer

  • Nizar M. Tannir

  • Bernard Escudier

  • Christian K. Kollmannsberger

  • Hans J. Hammers

  • Camillo Porta

  • Saby George

  • Frede Donskov

  • Howard Gurney

  • Marc-Oliver Grimm

  • Michael Roger Harrison

  • Thomas E. Hutson

  • Shuo Yang

  • Jennifer Johansen

  • Sumati Rao

  • Sabeen Fatima Mekan

  • Michael Rael

  • Thomas Powles

Medical Centers

  • Beth Israel Deaconess Medical Center, Boston, MA

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • U1015 INSERM, Gustave Roussy Cancer Campus, Paris Saclay University, Villejuif, France

  • The University of British Columbia, Vancouver, BC, Canada

  • UT Southwestern, Dallas, TX

  • University of Pavia, Pavia, Italy

  • Roswell Park Comprehensive Cancer Center, Buffalo, NY

  • Aarhus University Hospital, Aarhus, Denmark

  • Westmead Hospital and Macquarie University, Sydney, Australia

  • Essen University Hospital, Essen, Germany

  • Duke Cancer Institute, Duke University Medical Center, Durham, NC

  • Baylor Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, TX

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Monter Cancer Ctr, New York, NY

  • Evidera, San Francisco, CA

  • Barts Cancer Institute, Royal Free NHS trust, St. Bartholomew’s Hospital, London, United Kingdom

Locations

  • United States

  • France

  • Canada

  • Italy

  • Denmark

  • Australia

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Ipilimumab

  • Nivolumab

  • Sunitinib

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • NCT02231749

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved